Forte Biosciences, Inc. (FBRX)
NASDAQ
Market Cap
$34.28M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
268 of 963
Rank in Industry
160 of 552
Largest Insider Buys in Sector
FBRX Stock Price History Chart
FBRX Stock Performance
About Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Insider Activity of Forte Biosciences, Inc.
Over the last 12 months, insiders at Forte Biosciences, Inc. have bought $150,162 and sold $0 worth of Forte Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Forte Biosciences, Inc. have bought $226,228 and sold $4.45M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Riley Antony A (CHIEF FINANCIAL OFFICER) — $249,995. Wagner Paul A. (See Remarks) — $25,165.
The last purchase of 22,514 shares for transaction amount of $124,998 was made by Riley Antony A (CHIEF FINANCIAL OFFICER) on 2024‑11‑21.
List of Insider Buy and Sell Transactions, Forte Biosciences, Inc.
| 2024-11-21 | CHIEF FINANCIAL OFFICER | 22,514 0.5477% | $5.55 | $124,998 | +50.00% | |||
| 2023-12-18 | See Remarks | 10,000 0.0286% | $0.75 | $7,525 | -15.53% | |||
| 2023-12-14 | See Remarks | 10,000 0.0287% | $0.72 | $7,200 | -11.90% | |||
| 2023-12-13 | See Remarks | 10,520 0.0284% | $0.70 | $7,351 | -12.86% | |||
| 2023-12-12 | See Remarks | 4,776 0.013% | $0.65 | $3,088 | -6.84% | |||
| 2023-12-11 | See Remarks | 25,000 0.0719% | $0.65 | $16,188 | 0.00% | |||
| 2023-12-08 | See Remarks | 15,000 0.0406% | $0.62 | $9,300 | 0.00% | |||
| 2023-12-07 | See Remarks | 36,203 0.0971% | $0.58 | $21,168 | +5.17% | |||
| 2023-11-22 | See Remarks | 400 0.0011% | $0.43 | $172 | +37.86% | |||
| 2023-11-20 | See Remarks | 6,966 0.0175% | $0.44 | $3,048 | +21.00% | |||
| 2022-12-16 | See Remarks | 44,024 0.2759% | $1.07 | $47,000 | +2.04% | |||
| 2022-12-15 | See Remarks | 55,976 0.3253% | $1.03 | $57,672 | -1.96% | |||
| 2021-09-07 | Sale | See Remarks | 1M 7.2851% | $4.35 | $4.35M | -65.57% | ||
| 2021-09-07 | Sale | Chief Financial Officer | 25,000 0.1778% | $4.24 | $106,105 | -65.57% | ||
| 2020-06-29 | Chief Financial Officer | 2,000 0.0544% | $14.11 | $28,220 | +145.46% | |||
| 2020-06-26 | Chief Financial Officer | 4,700 0.1262% | $14.52 | $68,225 | +135.52% | |||
| 2020-06-25 | See Remarks | 7,000 0.1998% | $14.48 | $101,356 | +150.76% | |||
| 2020-04-14 | 10 percent owner | 74,301 0.1242% | $1.19 | $88,418 | +54.56% | |||
| 2020-03-02 | 10 percent owner | 65,149 0.0283% | $1.35 | $87,756 | -0.52% | |||
| 2019-05-30 | director | 43,000 0.0242% | $4.66 | $200,315 | -77.34% |
Insider Historical Profitability
69.41%
| Wagner Paul A. | See Remarks | 1823236 124.7143% | $23.45 | 12 | 1 | +50.28% |
| Riley Antony A | CHIEF FINANCIAL OFFICER | 30776 2.1052% | $23.45 | 3 | 1 | +140.49% |
| Oliveira Steven Michael | 10 percent owner | 2873450 196.5518% | $23.45 | 2 | 0 | +27.02% |
| Hasnain Faheem | director | 245857 16.8173% | $23.45 | 2 | 0 | |
| FOLETTA MARK G | EVP & Chief Financial Officer | 15042 1.0289% | $23.45 | 2 | 0 | |
| SCHIMMEL PAUL | director | 13623 0.9319% | $23.45 | 1 | 0 | |
| Duvall Martin J | Chief Executive Officer | 13605 0.9306% | $23.45 | 1 | 0 | |
| GRUBER HARRY E | President, Science&Innovation | 9744 0.6665% | $23.45 | 2 | 0 | |
| Das Asha | SVP & Chief Medical Officer | 2500 0.171% | $23.45 | 1 | 0 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Tybourne Capital Management HK Ltd | $2.52M | 9.95 | 3.62M | 0% | +$0 | 0.43 | |
| Perceptive Advisors | $2.27M | 8.96 | 3.27M | 0% | +$0 | <0.01 | |
| Bvf Inc Il | $2.09M | 8.18 | 2.98M | 0% | +$0 | 0.02 | |
| Alger | $1.28M | 5.05 | 1.84M | 0% | +$0 | 0.01 | |
| Farallon Capital | $1.27M | 4.97 | 1.81M | 0% | +$0 | 0.01 | |
| Bml Capital Management Llc | $1.23M | 4.83 | 1.76M | 0% | +$0 | 0.94 | |
| The Vanguard Group | $463,133.00 | 1.83 | 665,230 | 0% | +$0 | <0.0001 | |
| Geode Capital Management | $240,705.00 | 0.94 | 343,432 | +2.03% | +$4,784.91 | <0.0001 | |
| BlackRock | $121,736.00 | 0.48 | 174,858 | -4.09% | -$5,197.82 | <0.0001 | |
| Renaissance Technologies | $92,000.00 | 0.36 | 132,100 | +1.77% | +$1,601.82 | <0.0001 | |
| State Street | $29,194.00 | 0.11 | 41,664 | 0% | +$0 | <0.0001 | |
| Two Sigma | $28,450.00 | 0.11 | 40,864 | -0.24% | -$69.62 | <0.0001 | |
| Citadel Advisors LLC | $19,774.00 | 0.08 | 28,220 | +227.49% | +$13,735.99 | <0.0001 | |
| Northern Trust | $18,735.00 | 0.07 | 26,911 | 0% | +$0 | <0.0001 | |
| Two Sigma Advisers LP | $17,259.00 | 0.07 | 24,791 | 0% | +$0 | <0.0001 | |
| Goldman Sachs | $14,463.00 | 0.06 | 20,774 | +0.16% | +$23.67 | <0.0001 | |
| Group One Trading | $10,179.00 | 0.04 | 14,527 | -8.21% | -$910.90 | <0.0001 | |
| Aries Wealth Management | $9,051.00 | 0.04 | 13,000 | 0% | +$0 | <0.01 | |
| Tower Research Capital | $8,103.00 | 0.03 | 11,642 | +101.38% | +$4,079.34 | <0.0001 | |
| TWO SIGMA SECURITIES LLC | $7,743.00 | 0.03 | 11,122 | -27.93% | -$3,000.57 | <0.0001 | |
| HSBC | $7,529.00 | 0.03 | 10,745 | 0% | +$0 | <0.0001 | |
| Advisor Group Holdings Inc | $754.00 | <0.01 | 1,080 | 0% | +$0 | <0.0001 | |
| Morgan Stanley | $692.00 | <0.01 | 994 | 0% | +$0 | <0.0001 | |
| Russell Investments Group Ltd | $317.00 | <0.01 | 453 | 0% | +$0 | <0.0001 | |
| Loring Wolcott Coolidge Fiduciary Advisors Llp Ma | $139.00 | <0.01 | 193 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $176.00 | <0.01 | 253 | +2.02% | +$3.48 | <0.0001 | |
| UBS | $23.00 | <0.01 | 33 | -77.4% | -$78.76 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 137 | New | +$0 | <0.0001 | |
| Qube Research & Technologies | $2.00 | <0.01 | 3 | 0% | +$0 | <0.0001 | |
| JPMorgan Chase | $12.00 | <0.01 | 17 | 0% | +$0 | <0.0001 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.